Letybo 100 unit/vial is a Product of the Generic LetibotulinumtoxinA

What Is Letybo 100 unit/vial Indications and Uses?

Letybo 100 unit/vial (LetibotulinumtoxinA) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Pharmacology (Source, Chemical and Physical Composition) Of Letybo 100 unit/vial

Letybo 100 unit/vial (LetibotulinumtoxinA) blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine. When injected intramuscularly at therapeutic doses, LetibotulinumtoxinA is internalized into the nerve terminal, translocates into the neuronal cytosol where it cleaves SNAP25, a protein necessary for synaptic membrane docking and subsequent release of acetylcholine which produces a dose dependent decrease of muscle function. Recovery of muscle function is gradual due to degradation of the neurotoxin and formation of axonal sprouts. Muscle reinnervation occurs, leading to a slow reversal of the pharmacological effects of LetibotulinumtoxinA.

Dosage And Administration of Letybo 100 unit/vial

The recommended dose is 0.1 ml (4 Units) by intramuscular injection into each of five sites, for a total dose of 20 Units.

Drug Interactions of Letybo 100 unit/vial

No drug interaction studies have been conducted with Letybo 100 unit/vial (LetibotulinumtoxinA). Certain drugs may potentiate the effects of Letybo which may result in excessive neuromuscular weakness and heighten systemic anticholinergic effects. Use caution with concurrent use of Letybo with the following products and monitor closely for excessive neuromuscular weakness: Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products administered as the same time or within several months of Letybo Muscle relaxants administered before or after administration of Letybo

Side Effects of Letybo 100 unit/vial

The most common adverse reaction is headache (2%).

Precautions And Warnings for Letybo 100 unit/vial

Spread of toxin effects; swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Potency Units of Letybo 100 unit/vial (LetibotulinumtoxinA) are not interchangeable with other preparations of botulinum toxin products. Potential serious adverse reactions after Letybo injections for unapproved uses. If a hypersensitivity reaction occurs, discontinue Letybo and immediately initiate appropriate therapy. Adverse event reports have been received involving the cardiovascular system, some with fatal outcomes. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorder may exacerbate clinical effects of treatment. Use with caution in patients with compromised respiratory function or dysphagia.

Use During Pregnancy and Lactation

Pregnancy : Available data from case reports with Letybo 100 unit/vial (LetibotulinumtoxinA) use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Systemic exposure following intramuscular injection of letibotulinumtoxinA-wlbg was not assessed. In an animal reproduction study, intramuscular administration of letibotulinumtoxinA-wlbg to rats during pregnancy resulted in adverse effects on fetal growth (decreased fetal body weight and skeletal ossification) at maternally toxic doses 3 times the maximum recommended human dose (MRHD). Lactation : There are no data regarding the presence of letibotulinumtoxinA-wlbg in human or animal milk, its effects on the breastfed infant, or the effects on milk production. Systemic exposure following intramuscular injection of letibotulinumtoxinA-wlbg was not assessed. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LetibotulinumtoxinA and any potential adverse effects on the breastfed infant from LetibotulinumtoxinA or from the underlying maternal condition.

Therapeutic Class

Neurodegenerative Disease Drugs / Neuromuscular Disorder Drugs

Storage Conditions of It

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children. Pack Image: Letybo 100 unit/vial IM Injection Thanks for using MedEx! How would you rate your experience so far?